Showing 1 - 3 of 3 Prostate Cancers
Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm (ARASEC)

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Derek Cole

Phone: 713.441.5607

This is a phase 2 open label single arm study using an external control arm, to assess if the addition of darolutamide to ADT provides superior efficacy in terms of progression-free survival (PFS), as compared to ADT alone for men diagnosed with ... Read more >

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Open Not Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Status: Enrolling

Investigator: Eleni Efstathiou

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. ... Read more >